FDA Should Require Cardiovascular Outcomes Trials For All Type 2 Diabetes Drugs, Panel Says

Endocrinologic and Metabolic Drugs Advisory Committee asks the agency to eliminate a degree of risk for all candidates, even if no safety signal emerges from the clinical program.